Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1992009686) SUPPLEMENT FOR HYBRIDOMA CELL GROWTH MEDIUM
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1992/009686 International Application No.: PCT/GB1990/001826
Publication Date: 11.06.1992 International Filing Date: 26.11.1990
Chapter 2 Demand Filed: 11.05.1992
IPC:
C12N 5/16 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
12
Fused cells, e.g. hybridomas
16
Animal cells
Applicants:
THE SCOTTISH CROP RESEARCH INSTITUTE [GB/GB]; Invergowrie Dundee DD2 5DA, GB (AllExceptUS)
TORRANCE, Lesley [GB/GB]; GB (UsOnly)
REAVY, Brian [GB/GB]; GB (UsOnly)
Inventors:
TORRANCE, Lesley; GB
REAVY, Brian; GB
Agent:
CRUIKSHANK & FAIRWEATHER; 19 Royal Exchange Square Glasgow G1 3AE, GB
McCALLUM, William, Potter; Cruikshank & Fairweather 19 Royal Exchange Square Glasgow, G1 3AE, GB
Priority Data:
Title (EN) SUPPLEMENT FOR HYBRIDOMA CELL GROWTH MEDIUM
(FR) SUPPLEMENT POUR MILIEU DE CULTURE DE CELLULES HYBRIDOMES
Abstract:
(EN) A supplement for use in the production and growth of hydridomas comprises supernatant fluid from a culture of a human cervical carcinoma cell line, HeLa, during the log growth period of the culture (usually at day 3, 4 or 5). The supplement avoids the need to use feeder cells during growth of fused cells and cloning; or serum during growth for antibody production.
(FR) Supplément destiné à la production et à la culture des hybridomes. Il comporte un fluide surnageant provenant d'une culture d'une lignée cellulaire HeLa du cancer du col de l'utérus pendant la phase logarithmique de croissance de la culture (habituellement après 3, 4 ou 5 jours). Ce supplément rend inutiles l'utilisation de cellules nourricières pendant la croissance des cellules soudées et le clonage; et celle d'un sérum pendant la croissance destinée à la production d'anticorps.
Designated States: AU, CA, GB, JP, US
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1991068784